[Unsolved problems of cytoprotective therapy in patients with coronary heart disease].

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Терапевтический архив

• Publication date

  2015-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.17116/terarkh20158712101-106PMID 27022658
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies

  2014cited by this paper
• Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.

  2013cited by this paper
• Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association.

  2012cited by this paper
• Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities

  2010cited by this paper
• Myocardial fatty acid metabolism in health and disease.

  2010cited by this paper
• Trends in acute myocardial infarction incidence and mortality over 30 years in Japan: report from the MIYAGI-AMI Registry Study.

  2010cited by this paper
• Heart mitochondria: gates of life and death.

  2008cited by this paper
• Metabolic mechanisms in heart failure.

  2007cited by this paper
• Contribution of Triglyceride-rich Lipoproteins to Plasma Free Fatty Acids

  2007cited by this paper
• Metabolic therapy for patients with diabetes mellitus and coronary artery disease.

  2006cited by this paper
• Association of plasma free fatty acids and left ventricular diastolic function in patients with clinically severe obesity.

  2006cited by this paper
• Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy

  2005cited by this paper
• Myocardial substrate metabolism in the normal and failing heart.

  2005cited by this paper
• Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.

  2004cited by this paper
• Metabolic remodelling of the failing heart: the cardiac burn-out syndrome?

  2004cited by this paper
• Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.

  2003cited by this paper
• The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.

  2000cited by this paper
• Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project--Free Radicals.

  2000cited by this paper

• Metabolic therapy in cardiology from the perspective of evidence-based medicine

  2021cites this paper